A Phase 2/3, Two-Part, Open-Label, Dose Escalation, Age De-escalation and Randomized, Observer-Blind, Placebo-Controlled Expansion Study to Evaluate the Safety, Tolerability, Reactogenicity, and Effectiveness of mRNA-1273 SARS-CoV-2 Vaccine in Healthy Children 6 months to < 12 Years of Age (mRNA-1273-P204) - COVID-19

Status: Recruiting

Eligibility Criteria
This study is also accepting healthy volunteers

Conditions & Interventions

- Conditions: SARS-CoV-2
- Keywords: COVID-19, COVID-19 Vaccine, Coronavirus, Messenger RNA, Moderna, SARS-CoV-2, SARS-CoV-2 Vaccine, Virus Diseases, mRNA-1273, mRNA-1273 vaccine

More Information

- Description: The Sponsor of this study, ModernaTX, is studying the mRNA-1273 vaccine for the prevention of COVID-19 in children. This study is being conducted to learn about the safety, any side effects, and how your child’s body responds to the study vaccine (the immune response).
- Contact(s): Shane McAllister - smcallis@umn.edu
- Principal Investigator: Shane McAllister
- Phase: Phase II/III
- IRB Number: STUY00012613
- System ID: NCT04796896

Thank you for choosing StudyFinder. Please visit http://studyfinder.umn.edu to find a Study which is right for you and contact sfinder@umn.edu if you have questions or need assistance.